SCHEMBL6853274

SCHEMBL6853274

Cc1n[nH]c2ccc(-c3cncc(N(C[C@@H](N)Cc4ccccc4)S(C)(=O)=O)c3)cc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 14/20 0.48
CDK2 P24941 8/20 0.48
CDK7 P50613 6/20 0.48
PRKACA P17612 4/20 0.48
DAPK3 O43293 4/20 0.48
PAK4 O96013 4/20 0.48
CHEK2 O96017 4/20 0.48
PRKCG P05129 4/20 0.48
PIM1 P11309 4/20 0.48
RPS6KB1 P23443 4/20 0.48
MAPK1 P28482 4/20 0.48
AKT2 P31751 4/20 0.48
FLT3 P36888 4/20 0.48
CSNK1D P48730 4/20 0.48
MAPKAPK2 P49137 4/20 0.48
GSK3A P49840 4/20 0.48
GSK3B P49841 4/20 0.48
STK3 Q13188 4/20 0.48
CDC42BPA Q5VT25 4/20 0.48
IRAK4 Q9NWZ3 4/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6853276 1.00 AKT1 (0.48) AKT1CDK2CDK7PRKACADAPK3
SCHEMBL6854784 0.92 AKT1 (0.45) AKT1CDK2CDK7PRKACADAPK3
SCHEMBL6854779 0.92 AKT1 (0.45) AKT1CDK2CDK7PRKACADAPK3
SCHEMBL4791394 0.86 AKT1 (0.50) AKT1CDK2CDK7PRKACADAPK3
SCHEMBL4791387 0.86 AKT1 (0.50) AKT1CDK2CDK7PRKACADAPK3
SCHEMBL6855186 0.84 CDK2 (0.49) AKT1CDK2CDK7PRKACADAPK3
SCHEMBL6855183 0.84 CDK2 (0.49) AKT1CDK2CDK7PRKACADAPK3
SCHEMBL6855543 0.82 CDK7 (0.52) AKT1CDK2CDK7PRKACADAPK3
SCHEMBL6855539 0.82 CDK7 (0.52) AKT1CDK2CDK7PRKACADAPK3
SCHEMBL2191613 0.76 AKT1 (0.75) AKT1CDK2CDK7PRKACADAPK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6831175-B2 Such as N,N-dimethyl-N-(2-((5-((E)-2-pyridin-4-ylvinyl) pyridin-3-yl)oxy)ethyl)amine ABBOTT LABORATORIES 2004-12-14 US claimed
EP-1463505-A2 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER Abbott Laboratories (US) 2004-10-06 EP claimed
US-20030199511-A1 Kinase inhibitors ABBVIE INC. 2003-10-23 US claimed
US-20030187026-A1 Kinase inhibitors ABBOTT LABORATORIES 2003-10-02 US claimed
WO-2003051366-A2 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER ABBOTT LABORATORIES (US) 2003-06-26 WO claimed
US-6831175-B2 Such as N,N-dimethyl-N-(2-((5-((E)-2-pyridin-4-ylvinyl) pyridin-3-yl)oxy)ethyl)amine ABBOTT LABORATORIES 2004-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030187026-A1 Kinase inhibitors MAP3K20, MAP3K19, MAP3K1 AKT1 119/4885CDK2 28/4885CDK7 66/4885
US-20030199511-A1 Kinase inhibitors MAP3K20, MAP3K19, MAP3K1 AKT1 119/4885CDK2 28/4885CDK7 66/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.